Disclosed the use of an antagonist of signal transducer and activator of transcription 3 (STAT3) in the manufacture of a medicament for the treatment of a breast condition, wherein the ER/PR status of a diseased tissue in said subject is ER+/PR+ and the PAX2-to-DEFB1 expression ratio is in said diseased breast tissue is increased compared to the PAX2-to-DEFB1 ratio in normal breast tissue.
